Gene

DDX43

DEAD-box helicase 43

Explore in graph →CI-GENE-00043127HGNC:18677 ENSG00000080007 NCBI 55510 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DDX43 Overexpression1
Mirdametinib + Selumetinib + TrametinibSubstitutes	Uveal Melanoma	Predictive	D	Supports Resistance	4	accepted	EID1135 MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines. Overexpression of DDX43 mediated RAS-induced selumetinib resi… (full text at CIViC) PMID 24899684 · Ambrosini et al., 2014 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (3)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Acral Melanoma (TGEN, Genome Res 2017) mel_tsam_liang_2017	Melanoma	Ssm	3	38	7.9%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
· Mol Cancer Ther · 2014 · PMID 24899684 · validated civic_curation pubmed